STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
Biogen has reported mixed results from a mid-stage trial of its Alzheimer’s treatment diranersen, which showed promise in reducing tau levels and slowing cognitive decline, though it requires spinal injection. Meanwhile, Takeda Pharmaceutical plans to cut 4,500 jobs as part of a restructuring effort aimed at reducing costs and improving efficiency following its acquisition of Shire.
Biogen's Phase 2 trial of diranersen for Alzheimer's, targeting tau protein, showed a reduction in tau levels and correlated cognitive decline slowing, although it requires spinal injections. This presents an opportunity to explore alternative administration methods or partner with companies developing innovative delivery systems to enhance patient compliance and broaden market potential.